PUBLICATION

Targeting ganglioneuromas with mTOR inhibitors

Authors
Tao, T., Shi, H., Durbin, A.D., Look, A.T.
ID
ZDB-PUB-210209-11
Date
2021
Source
Molecular & cellular oncology   8: 1856621 (Other)
Registered Authors
Durbin, Adam, Look, A. Thomas
Keywords
AKT, Ganglioneuroma, mTOR inhibitor, zebrafish model
MeSH Terms
none
PubMed
33553609 Full text @ Mol Cell Oncol
Citation
Tao, T., Shi, H., Durbin, A.D., Look, A.T. (2021) Targeting ganglioneuromas with mTOR inhibitors. Molecular & cellular oncology. 8:1856621.
Abstract
We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas prior to surgical resection.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.